Team

Mr. Yu is the founder, CEO and CIO of Ally Bridge Group, a leading global life science-dedicated investment group. Mr. Yu carries a strong track record as an investment manager across multiple funds and strategies with investments in  the U.S., China and Europe. Mr. Yu started his career in New York, then worked in Hong Kong for over two decades. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to OZ, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.

Since 2010, Mr. Yu has founded, launched and managed multiple funds covering venture, growth, buyout and hedge fund investing from China to U.S. to Europe.  Mr. Yu excels in originating and executing major investment themes such as global life science investing, which has become the primary focus of Mr. Yu and Ally Bridge, creating high-impact deals such as the landmark US$3.3 billion WuXi Pharmatech. He has expertise in cementing strategic transactions between emerging players and industry leaders across the U.S., China and Europe.

  • Anna Yaeger is the portfolio manager of ABG New York office and a Partner of ABG. She is responsible for managing US and European public equity positions managed by ABG. Ms. Yaeger has extensive experience in hedge fund portfolio management. Prior to ABG, Ms. Yaeger spent 12 years at SAC Capital/Point 72. She served as a Portfolio Manager for a long-short healthcare portfolio for 4 years and was a Senior Research Analyst for a healthcare portfolio prior to that. As a Portfolio Manager, she generated positive absolute and alpha returns for her fund every year. She invested in all sectors in the healthcare space across the US, Europe and Japan. Before joining SAC Capital/Point 72, Ms. Yaeger worked at Goldman Sachs in the Healthcare Investment Banking Group in New York. She graduated magna cum laude from The Wharton School at the University of Pennsylvania with a BS in Economics.
  • Dr. Hong Zheng has over 10 years’ of experience in biotechnology, working across the fields of finance, industry and academia. Before joining Ally Bridge Group, Dr. Zheng was a senior equity research associate at Royal Bank of Canada capital markets, covering over 30 US biotech companies. Prior to RBC, Dr. Zheng was a medicinal chemist at Ra Pharmaceuticals for three years, where he led several drug discovery programs including small molecule and peptide drug candidates that later have entered into clinical stage. Dr. Zheng completed his Bachelor’s degree from Fudan University and received his PhD in Chemical Biology from Boston College, where he published many highly impactful research articles in top ranked journals as the first author.
  • Steven Plachtyna is a Research Analyst at Ally Bridge Group and focuses on Medical Technology and Life Science Tools and Diagnostics investments based in New York. Before joining Ally Bridge Group, Mr. Plachtyna was a Senior Equity Research Associate at Citi Group and Bank of Montreal Capital Markets, covering the Medical Technology sector. Prior to BMO, Mr. Plachtyna was a Development Engineer at Medtronic, where he supported the commercialization of its surgical stapling platform. Mr. Plachtyna holds a Bachelor’s degree in Biomedical Engineering from the University of Connecticut and received a Masters of Engineering in Biomedical Engineering and MBA from Cornell University.
  • Tian Sun joined Ally Bridge Group as a research analyst in 2021, where he currently covers the biotechnology sector. Prior to Ally Bridge Group, Tian was an equity research associate at Needham & Company, covering over 25 US companies across both biopharma and specialty pharma sectors. Tian is a pharmacist by training, with over 5 years of experience across both retail and clinical pharmacy settings. Tian received his Doctor of Pharmacy (PharmD) degree from Rutgers University.
  • Charles Chon is a Partner and Managing Director of Ally Bridge Group. Mr. Chon leads ABG’s Medical Technologies effort and is a member of ABG’s Investment Committee. Before joining ABG in 2013, Mr. Chon had been a healthcare public equity research analyst for over 13 years on both buy-side and sell-side, mostly as Vice President and senior equity research analyst at Goldman Sachs on the US medical devices team. From there, Mr. Chon became the Sector Head for US medical devices research at Stifel Nicolaus. Mr. Chon began his career on Wall Street at ABN AMRO and also covered the healthcare sector from the buy-side at Fred Alger Management. Mr. Chon holds CFA designation, and received his MBA in healthcare management from Boston University and BA in Chemistry from Amherst College.
  • Andrew Pang is a Managing Director of Ally Bridge Group and focuses on medical devices investments and private equity transactions. He joined the team led by Frank Yu in 2011 and has since played an important role in underwriting and executing notable transactions including the take-private of WuXi Pharmatech and Shandong Luoxin Pharmaceutical as well as the Series C investment in GRAIL, Inc. Before joining ABG, Mr. Pang worked at InterLeader, a family-office investment group in Hong Kong, focusing on private equity transactions. Prior to returning to Hong Kong, Mr. Pang worked at Bank of America in London, where he worked on European leveraged buyout transactions. Mr. Pang has developed excellent deal execution skills and cross-border investment experience. Mr. Pang holds a BA in Mathematics and Computer Science from the University of Cambridge where he graduated with first class honors.
  • Reese Yeh is a Managing Director of Ally Bridge Group and focuses on private equity transactions and biopharma investments. She joined the team led by Frank Yu in 2012 and has since played an important role in underwriting and executing notable transactions including the take-private of WuXi Pharmatech and the investment in Vifor Pharma. Prior to joining ABG, Ms. Yeh was with Morgan Stanley Private Equity Asia, focusing on private equity transactions in Greater China and Southeast Asia. Ms. Yeh holds a BBA in Finance from National Taiwan University.
  • Kevin Reilly is a Managing Director, Special Investments, of Ally Bridge Group (PE) LLC and is based in New York City. Mr. Reilly is focused on private equity transactions across a variety of healthcare sectors including medical technologies, diagnostics, digital health and services. Before joining ABG in 2021, Mr. Reilly was a Principal at CRG, a healthcare investment firm that provides growth capital to companies across the healthcare spectrum through the form of long-term debt and equity. Prior to CRG, Mr. Reilly spent several years in investment banking at Stifel advising healthcare companies in capital markets and M&A initiatives. Mr. Reilly holds a B.S. in Finance and Information Systems from the University of Maryland.
  • Dr. Andrew Lam is a Senior Vice President, Special Investments, of Ally Bridge Group (PE) LLC and focuses on private equity therapeutics investments. Dr. Lam brings over 15 years of biopharma-focused experience across industry, equity research, and investment banking. Dr. Lam joined Ally Bridge Group from Intercept Pharmaceuticals where he was Senior Director of Business Development. Prior to Intercept, Dr. Lam spent many years on Wall Street, most recently as Vice President of Healthcare Investment Banking at Jefferies where he completed over 30 biopharma financing and M&A transactions, and equity research associate at BMO Capital and Canaccord Genuity, where he covered biotech. Prior to Wall Street, Dr. Lam spent nearly a decade in medical affairs roles at several biotech companies, including Celgene and Shire, with a focus on oncology and rare diseases. Dr. Lam is a pharmacist by training and holds a PharmD from Long Island University and MBA from Drexel University.
  • Tinnie Chau is a Vice President at Ally Bridge Group and focuses on biopharma and biotech investments. She joined Ally Bridge Group in 2015 and has since participated in the execution as well as portfolio management of all the biopharma investments of the group. Prior to joining ABG, Ms. Chau worked as a Manager at the Corporate Finance department of PwC, providing advisory services on M&A transactions across industries with a number of transactions in the healthcare sector. Ms. Chau holds a BA and MA in Biological Natural Sciences from the University of Cambridge, specialized in Pathology and Microbiology. Ms. Chau is a CFA® Charterholder.
  • Barney Han is a Vice President at Ally Bridge Group and focuses on ABG’s private equity transactions and medical devices investments. Mr. Han joined the ABG platform in 2014 and played an important role in executing notable transactions including the take-private of WuXi Pharmatech and Shandong Luoxin Pharmaceutical. Previously Mr. Han was a private equity investment analyst at LionRock, where he was involved in private equity investments with a particularly strong coverage of China related deals. Mr. Han holds a CFA Level III and FRM II certification and both an MSc in Finance from Hong Kong University as well as a BA in Economics from Nankai University.
  • Sebastian Paquette, CFA is a Vice President at Ally Bridge Group (PE) LLC and focuses on ABG’s private equity transactions within the digital health, medical devices, and diagnostics sectors. Before joining ABG in 2021, Mr. Paquette was the Director of Healthcare for 7 years at Solid Rock Group, an investment and advisory firm. Prior to Solid Rock Healthcare, Mr. Paquette founded two healthcare companies focused on surgeon practice restructuring and medical device supply chain efficiency. Mr. Paquette began his healthcare career at Goldman Sachs, where he spent 7 years as a healthcare equity research analyst across several subsectors and was the lead HCIT equity research analyst. Mr. Paquette is a CFA® charterholder, and received a BA in Psychology from Boston College.
  • Jiayun Zhou is an Associate at Ally Bridge Group and focuses on medtech and life science tools & diagnostics investments. Prior to joining Ally Bridge Group in 2019, Ms. Zhou was a Corporate Finance Analyst at Yuexiu Group. Ms. Zhou holds a CFA Level III certification and both a BA in Economics from the University of Cambridge, and an MSc in Finance from the University of Hong Kong.
  • Amy Herrup joined Ally Bridge Group in 2021 and is Head of Business Development and Investor Relations based in New York. In this capacity, Amy is responsible for managing communications with investors, leading capital raising efforts and contributing to strategic firm-wide initiatives. Most recently, Amy was a Director on the Client Solutions team at Capstone Investment Advisors, LLC (Capstone), an alternative investment manager specializing in volatility, where she helped lead distribution to institutional investors globally across products. Before joining Capstone, Ms. Herrup managed investor relations at Varadero Capital, LP, an asset manager focused on specialized credit across the securitized and non-securitized spaces. Ms. Herrup began her career at Goldman Sachs where she spent nearly a decade in the Securities Division, initially in Short Term Interest Rate Sales in Chicago before later moving to Mortgage Sales in New York. Amy holds a Bachelor of Arts in Economics and Mathematical Methods in the Social Sciences from Northwestern University. She is currently a Level III Candidate in the CFA Program.
  • Daniel Johnson is the Chief Financial Officer for Ally Bridge Group (NY) LLC. Prior to joining ABG, Dan has over 30 years of experience in finance, operations and accounting. His experience over the past 10 years in asset management have included roles as Head of Finance and Administration and Compliance at Elenion Capital, a macro alpha capture manager, Chief Financial Officer and Chief Compliance Officer at Castle Ridge Investment Management, a real estate focused equities hedge fund manager and Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer Trend Capital Management, a manager running global macro portfolios. Dan is a Certified Public Accountant and has worked in various other roles on the buy-side and the sell-side, in New York and London, including roles at a family office, Tiger Management and Morgan Stanley.
  • Michael Bendetson is Director of Legal & Compliance at Ally Bridge Group. Mr. Bendetson is responsible for ensuring ABG’s compliance with U.S. and international laws and regulations. Before joining ABG, Mr. Bendetson was a Capital Markets Associate at Paul, Weiss, Rifkind, Wharton & Garrison LLP, where he advised clients on public and private offerings of debt and equity securities, and general corporate and securities law matters. Prior to Paul Weiss, he worked as a Derivatives and Structured Products Associate for Davis Polk & Wardwell LLP. Mr. Bendetson contributed to Financial Regulation: Law and Policy (Foundation Press), a leading law school textbook on the subject. He has also served as a co-author for Insights: The Corporate and Securities Law Advisor, a publication that analyzes recent developments in corporate and securities law. Mr. Bendetson graduated magna cum laude from Tufts University with a B.A. in Political Science. He received his J.D. from the University of Michigan Law School.
  • Eric Kwong is the Head of Operations for Ally Bridge Group (NY) LLC. Eric has over 9 years of experience focusing on alternative investment operations and finance. Prior to ABG, he was Vice President, Operations & Finance for Jacobs Asset Management, an established asset manager focusing on investing in the financial services space. Eric started his career at Citigroup as a hedge fund accountant before moving to Vastardis Capital Services as a middle office analyst. Eric has a BBA in Finance from Baruch College.
  • Charles Wong, CPA, is the Chief Financial Officer for Ally Bridge Group in Hong Kong. Prior to joining ABG, Charles had over 15 years of experience in alternative asset management primarily focused on private equity – as well as hedge fund -- finance and operations. Previously, Charles was the Chief Financial Officer at TR Capital, an Asia-Pacific secondary and primary private equity and hedge fund investment fund group based in Hong Kong. Prior to TR Capital, Charles was a Vice President, Finance, at CITIC PE, a leading private equity group in China. Before CITIC PE, Charles was the Financial Controller at DST in Hong Kong, a leading global late-stage Internet technologies investment specialist. Before DST, Charles worked as an auditor at Deloitte in Hong Kong, New York and Beijing. Charles is a Member of the Hong Kong Institute of Certified Public Accountants and graduated from the Hong Kong University of Science and Technology, where he received a Bachelor’s Degree in Accounting and Finance.
  • Bowie Pang is the Financial Controller at Ally Bridge Group in Hong Kong. Bowie has over 10 years of experience in alternative asset management primarily focused on private equity finance and operations. Prior to joining ABG, she was the Financial Controller at Fulcrum Global, a Hong Kong based real estate investment group with over US$1 billion invested capital. Before that, Bowie worked with TR Capital, a secondaries-focused Asian private equity and hedge fund investment group in Hong Kong. Bowie started her career with SSG Capital, a pan-Asian alternative asset manager focuses on special situations and credit investments with over US$6 billion assets under management, where she spent over 8 years working across middle/back office functions in the private equity field. Bowie received her Bachelor degree in Economics from Loughborough University in England.
  • Sharon Lam is Finance Manager for Ally Bridge Group in Hong Kong. She has over 6 years of PE finance experience. Prior to joining ABG, she was the Finance Manager at Welkin Capital, a Asia-focused growth equity investment firm. Sharon received her bachelor degree in Commerce from Macquarie University in Australia. She is a member of CPA Australia.
  • Mr. Boone, who had dedicated 28 years to Amgen, is one of the most accomplished drug discovery and development scientist in the biotech industry. As Global Head of Protein Science at Amgen, Mr. Boone led the successful development of several blockbuster biologic drugs including Neupogen, Neulasta and N-plate, in addition to his involvement in many other drugs successfully developed at Amgen. Apart from being a highly productive drug discovery scientist with strong biologic manufacturing expertise, Mr. Boone led and mentored a group of over 300 scientists at Amgen. His wealth of biotech knowledge, network and commercial successes are highly valuable to ABG’s investment effort in the biopharmaceutical field, especially in terms of in-depth due diligence and portfolio management.
  • Dr. Li, with over 30 years of experience in the life sciences sector, joins ABG from Pfizer (Boston) where he was Executive Director and Head of Biotherapeutic Technologies. Prior to Pfizer, Dr. Li spent over 18 years at Amgen in pharmaceuticals research and development. Prior to Pfizer, Dr, Li was in the academia, as a clinical professor at the Washington University School of Medicine. Throughout his career, Dr, Li advanced more than three dozen product candidates from discovery, preclinical, manufacturing to clinical development. Dr, Li holds an MD and MS in Pharmacology from Fujian Medical University.